Immunotherapy combination for MSI-H stomach cancer before surgery
Part of Cancer, Digestive system, Immune system & allergy clinical trials.
This trial tests a combination of immunotherapy, anti-angiogenic therapy (which cuts off blood supply to tumors), and chemotherapy in people with a specific type of stomach cancer that has certain genetic markers (MSI-H/dMMR). The goal is to see if this combination can make previously inoperable tumors shrink enough for surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have locally advanced or metastatic stomach or gastroesophageal (GEJ) cancer that cannot be removed by surgery.
- You have not received any prior chemotherapy, immunotherapy, or targeted therapy for your advanced or metastatic cancer.
- Your tumor tests as MSI-H or dMMR (special markers that may make immunotherapy more effective).
- Your tumor has a low PD-L1 score (less than 1) and is not HER2-positive.
- You are in generally good health (ECOG 0-1, meaning you can take care of yourself and are up and about).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs plus chemotherapy as a first treatment for advanced stomach or gastroesophageal junction cancer. The goal is to see if this approach helps shrink tumors and improve survival compared to standard treatment.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) for people with advanced gastric cancer that has a specific DNA repair problem (MSI-H/dMMR). It is for those who have not yet had any treatment for their advanced cancer.
This trial tests a combination of immunotherapy, anti-angiogenic therapy, and chemotherapy for people with advanced stomach or gastroesophageal junction cancer that hasn't been treated before. It is designed for those whose tumors have low PD-L1 levels.
This trial tests two immunotherapy drugs given before surgery for locally advanced gastric cancer that has a specific genetic marker (MSI-H or dMMR). The goal is to shrink the tumor and improve outcomes before removing it surgically.
This trial tests whether adding an immunotherapy drug (QL1706) to a standard chemotherapy regimen, given before surgery, can help shrink stomach or gastroesophageal junction cancer. The goal is to improve the chance of successful surgery and long-term outcomes.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with chemotherapy (SOX) and targeted radiation for people with advanced stomach or gastroesophageal junction cancer that hasn't been treated yet. The goal is to see if this approach helps shrink tumors or slow the disease.
Hear when a new Gastric or Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.